Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs: Endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology

• Published in: Journal of vascular and interventional radiology Vol. 32; no. 8; pp. 1241.e1 - 1241.e12
• Main Authors: Genshaft, Scott J, Suh, Robert D, Abtin, Fereidoun, Baerlocher, Mark O, Chang, Albert J, Dariushnia, Sean R, Devane, A Michael, Faintuch, Salomao, Himes, Elizabeth A, Lisberg, Aaron, Padia, Siddharth, Patel, Sheena, Tam, Alda L, Yanagawa, Jane
• Format: Journal Article
• Language: English
• Published: United States 01-08-2021
• Subjects: Canada; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - surgery; Catheter Ablation; Humans; Lung; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - surgery; Neoplasm Recurrence, Local; Radiology, Interventional; Retrospective Studies; Canada
• ISSN: 1535-7732
• DOI: 10.1016/j.jvir.2021.04.024

To state the Society of Interventional Radiology's position on the use of image-guided thermal ablation for the treatment of early stage non-small cell lung cancer, recurrent lung cancer, and metastatic disease to the lung.
A multidisciplinary writing group, with expertise in treating lung cancer, conducted a comprehensive literature search to identify studies on the topic of interest. Recommendations were drafted and graded according to the updated SIR evidence grading system. A modified Delphi technique was used to achieve consensus agreement on the recommendation statements.
A total of 63 studies, including existing systematic reviews and meta-analysis, retrospective cohort studies, and single-arm trials were identified. The expert writing group developed and agreed on 7 recommendations on the use of image-guided thermal ablation in the lung.
SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease.